Vaxart, Inc. (VXRT)

0,7662 +0,0373 (+5,12%) Börsenschluss: 04:00PM EDT

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 109

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Sean N. Tucker Ph.D.	Senior VP & Chief Scientific Officer	561,1k	N/A	1968
Dr. James F. Cummings M.D.	Chief Medical Officer	594,5k	N/A	1966
Mr. Steven Lo	President, CEO & Director	N/A	N/A	1967
Mr. Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1988
Dr. Raymond D. Stapleton Jr., Ph.D.	Chief Technology Officer	N/A	N/A	1971
Mr. Edward B. Berg	Senior VP & General Counsel	N/A	N/A	1964
Ms. Shaily Jaini Garg	Senior Vice President of Clinical Development & Project Management	N/A	N/A	N/A
Dr. Rajesh Kapoor Ph.D.	Senior Vice President of Quality	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Corporate Governance

Vaxart, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 6, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.